Coronary/Structural Heart

Neovasc Named Finalist in Questex’s Fierce Innovation Awards LifeSciences Edition 2019

VANCOUVER, Dec. 04, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN): NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has been […]

Repairing children’s heart valves with patients’ own tissues at Stanford Children’s Health

Cardiac surgeons at Lucile Packard Children’s Hospital Stanford introduce the Ozaki procedure for pediatric patients STANFORD, Calif., Dec. 4, 2019 /PRNewswire/ — On Nov. 22, cardiothoracic surgeons at Lucile Packard Children’s Hospital Stanford began offering an innovative repair for children’s heart valves. The method, called the Ozaki procedure, involves crafting a new heart valve from the […]

CHF Solutions Announces Launch of Ultrafiltration Therapy Using Aquadex FlexFlow® System at Memphis Methodist Le Bonheur Healthcare System

EDEN PRAIRIE, Minn., Dec. 03, 2019 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS) today announced that Memphis, Tennessee-based health system, Methodist Le Bonheur, has initiated offering aquapheresis therapy to patients suffering from fluid overload using the company’s Aquadex FlexFlow system. The use of the therapy was featured in the Daily […]

MCRA Assists CorFlow in Obtaining Breakthrough Device Designation

WASHINGTON, Dec. 3, 2019 /PRNewswire/ — MCRA, LLC, a leading medical device advisory firm and Clinical Research Organization (CRO) that integrates regulatory, clinical research, reimbursement, compliance and quality assurance, is pleased to announce its role in the successful granting of a Breakthrough Device Designation for the CorFlow Therapeutics AG Controlled Flow Infusion (CoFITM) […]

Bracco Diagnostics Inc.’s LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use, receives U.S. Food and Drug Administration approval for use in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in pediatric patients with suboptimal echocardiograms

MONROE TOWNSHIP, N.J., Dec. 2, 2019 /PRNewswire/ — Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business, announced today that its contrast agent LUMASON is the first ultrasound enhancing agent (UEA) to obtain U.S. Food and Drug Administration (FDA) approval for […]

Neovasc Reducer™ Featured In FOCUS Magazine

VANCOUVER, CA, and BERLIN, DE, Nov. 26, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that […]

Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca

Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing over US$100B per year Drug developers currently lack effective humanized models for preclinical testing of targeted drug candidates in heart failure with preserved ejection fraction The collaboration aims to provide a unique solution for […]

Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia

On track to report topline results for TRILOGY 1 in December 2019 and TRILOGY 2 in January 2020 LAVAL, Québec, Nov. 26, 2019 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its […]

OTITOPIC™ New Clinical Trial Results Continue to Demonstrate Inhibition of Platelet Aggregation in Two Minutes With Dry Powder Inhalation of Aspirin Formulation for High Risk Patients to Treat Suspected Acute Myocardial Infarction (MI)

LOS ANGELES–(BUSINESS WIRE)–OTITOPIC – A clinical-stage dry powder inhalation of aspirin pharmaceutical company pioneering the development of antithrombotic treatments for use at the time of suspected acute myocardial infarction (MI), today announced the successful conclusion based on PD results of a clinical trial for its lead drug: Dry Powder Inhalation […]

Eko Makes Stethoscopes Even Smarter with the Redesigned CORE

The redesigned Eko CORE boasts active noise cancellation, sleeker design, and powerful software to allow medical professionals to more effectively screen for heart disease San Francisco, CA, Nov. 25, 2019 (GLOBE NEWSWIRE) — Eko, a digital health company with an AI-powered cardiac screening platform, today announced the second generation of its CORE […]